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falciparum dihydroorotate dehydrogenase 
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Malaria 
Malaria is a parasitic disease caused by five species of the genus Plasmodium (P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi) that affect humans. The most 
deadly form of Malaria is due to Plasmodium Falciparum and it is mostly spread in African 
areas (Figure 1). In this region, P. ovale has replaced P. vivax since African people have 
lost the Duffy antigen which is the receptor P. vivax uses to infect human erythrocytes. P. 
vivax  is less dangerous but more widespread, furthermore a dormant stage (hypnozoites), 
as well as in P. ovale infections, can persist in the liver and cause relapses by invading the 
bloodstream weeks, or even years later.i 
 
Figure 1. Reported malaria cases in 2011 (source: Kalser Family Foundation, www.GlobalHealthFacts.org, based on 
WHO, world malaria report 2012. 
 
In 2011 there were an estimated 3.3 billion people at risk of Malaria and among these the 
more affected by the disease were children under five years of age and pregnant women. 
Today Malaria is a completely preventable and treatable disease if the currently 
recommended interventions are properly implemented. The parasite is transmitted by the 
bite of female mosquitoes of over 30 Anopheles species. Anopheles Gambiae is one of the 
most common vehicle of infection since it prefers to feed with human blood over animals 
and it is responsible for most infections in the sub-Sahara regions. The most effective 
efforts to defeat this plague and decrease the spreading of it are: 
 vector (mosquito) control by using of insecticides treated nets (ITNs), indoor 
residual spraying and larval control (rainfalls can create collections of water where 
Anopheles eggs are deposited, and larvae and pupae develop into adulthood); 
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 chemoprevention; 
 confirmation of malaria diagnosis; 
 timely treatment with appropriate antimalarial medicines. 
It is estimated that in 2010, 660,000 deaths were caused by Malaria and 219 million 
people were affected by the diseaseii. However from 2000 to 2010 there has been a 
decrease in deaths rates of 26% and of 17% in the incidence rates but the eradication of 
the parasite is still far. More than 80% of deaths occur in 14 countries while 17 countries 
represent the 80% of worldwide cases.  
 
 
Malaria treatments 
The first medicine used to treat malaria was an active principle extracted from the bark of 
the cinchona tree called quinine. Quinine has a marked bitter taste which gives the well 
known taste to tonic water. In fact, originally tonic water contained just spring water and 
quinine and was consumed by British officers during colonial times, often served with gin, 
to avoid malaria contamination. Around mids of XXth century, chloroquine was introduced 
as a cheap malaria drug. It saved millions of lives and helped to reduce the malaria 
spread. However in few years, parasites developed resistant strains to chloroquine and the 
burden of malaria increased again. Chloroquine was replaced with sulfadoxine-
pyrimethamine combination, but the drawback of important side-effects did not allow this 
treatment for prophylactic useiii. Again, the spread of resistance has ended the use of 
sulfadoxine-pyrimethamine alone. 
Today the guidelines for treatment of chloroquine-resistant uncomplicated malaria from P. 
falciparum are atovaquone-proguanil (MalaroneTM); artemether-lumefantrine (CoartemTM); 
quinine sulfate plus doxycycline, tetracycline or clindamycin; mefloquine (LariamTM and 
generics). Guidelines for treatment of chloroquine-sensitive uncomplicated malaria from Pf 
suggest the use of chloroquine phosphate (AralenTM and generics) or hydroxychloroquine 
(PlaquenilTM and generics). Severe malaria should be treated with quinine gluconate plus 
doxycycline, tetracycline or clindamycin (intravenous); otherwise it should be treated with 
artesunate followed by one of the following: atovaquone-proguanil (MalaroneTM), 
doxycycline (clindamycin in pregnant women), or mefloquine.iv 
Currently there are several drugs on market to treat malaria. The problem is the 
effectiveness of these drugs since the parasite develops resistance quite fast. In fact 
studies showed that the parasite uses a two-steps process which assists the plasmodium 
in finding productive solutions to new and unexpected evolutionary challengesv: it has 
been demonstrated that some haploid blood-stage parasites first survive antimalarial 
pressure through fortuitous DNA duplications that always included the DHODH gene. 
Parasites have different sized amplification units but they are always flanked by distant 
adenine/thymine tracks. Higher level amplification and resistance is attained using a 
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second, more efficient and more accurate, mechanism for head-to-tail expansion of the 
founder unit. Furthermore, recent studies confirmed the evidence of a decreased 
effectiveness of artemisinin combination therapies (ACT) in western Cambodia vi . 
Therefore, it is important to discover new targets and new chemotherapeutics to defeat 
this plague since the best vaccine candidate (RTS,S) provided just moderate protection in 
a phase 3 trial on African infantsvii. 
 
Biological background 
Dihydroorotate dehydrogenase (DHODH) is an enzyme that converts dihydroorotate to 
orotate by an oxidative reaction in the fourth, rate-limiting step of de novo synthesis of 
pyrimidines (Figure 2). Pyrimidines are essential in the synthesis of RNA and DNA which 
permit the transfer of genetic information from cells to daughter cells. If a cell is not able to 
synthetize own RNA or DNA, it will die. A human cell can acess pyrimidines by salvage of 
used pyrimidines or by de novo synthesis. If de novo synthesis is inhibited the cell will rely 
on the salvage pathway and the cell will not die, however since Plasmodium species lack 
the pyrimidine salvage pathway, inhibition of de novo synthesis in parasite cells will cause 
the death of those cells which makes the parasite vulnerable to inhibition of DHODH. 
 
Figure 1. The fourth step in pyrimidine biosynthesis catalyzed by DHODH. Source: Liu et al.
viii 
 
Dihydroorotate dehydrogenase 
DHODHs are divided into two classes depending on their primary structure, localization 
and final electron acceptor. ix Gram-positive bacteria and few unicellular eukaryotes are 
included in Class 1 and their DHODH is soluble and localized in the cytosol; Class 1 can 
be further divided in other subtypes, type 1A and 1B.x Unlike Class 1 DHODHs, in Class 2 
the enzyme is linked to the inner membrane of mithocondria and it is found in Gram-
negative bacteria, in humans, insects, plants and parasites. The overall structure of 
DHODHs is an α/β barrel which consists of eight parallel β strands surrounded by eight α 
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helices and two sets of antiparallel β strands at the top and the bottom of the barrel. The 
function of the DHODH can be simplified in two half-reactions: the first one, which is the 
oxidation of dihydroorotate into orotate with FMN as co-factor, is common to Class1 and 2; 
however, the two classes differ in the use of final electron acceptor during the second half-
reaction of the enzyme: Class 2 enzymes use ubiquinone while Class 1-type A use 
fumarate as the latest electron acceptorxi and 1-B enzymes use first FAD and then NAD+.xii 
This is not the only difference between Class1 and 2: a very important dissimilarity is the 
amino acid residue, which act as the catalytic base in the first step of the reaction. In class 
2 DHODH the catalytic residue is a serine, which is very well conserved and it is the 
closest residue to C5 position of dihydroorotate. However, in Class 1 the catalytic base is 
not a serine, but a cysteine instead.ixb The role of the catalytic base is to remove the proton 
from C5 of dihydroorotate, but for doing it the residue must first be deprotonated: since 
there are not residues in its environment that can deprotonate it and the substrate contains 
a negative charge, it is assumable that the deprotonation is due to the substratexiii. Another 
big difference between Class1 and 2 is the extended N terminus at the side of the main 
barrel, which is missing in Class1; in fact, the first part of the N-terminal domain is 
important for the binding to the mithocondrial membrane and allows the CoQ to reach the 
DHODH active siteviii. N-terminal domain folds in two α-helices and a short 310 helix, which 
are connected to the α/β barrel by a long loop. Liu et al. found that the N-terminal domain 
of the human enzyme in complex with brequinar, as well as with A77 1726 (the active form 
of leflunomide) hosts the quinone binding site and this function is kept also in E. coli xii. 
These α-helices and the side of the α/β barrel create an hydrophobic tunnel which ends up 
to FMN and was initially identified as the binding site for DHODH inhibitors and for CoQ. 
Further studies, however, demonstrated that ubiquinone binding site does not overlap with 
inhibitors site, but nevertheless the binding of an inhibitor prevent the binding of the 
ubiquinone. 
Even if the fold and the active site of the hydrophobic tunnel is very similar among Class 2 
enzymes, the regions near the binding site may differ from one organism to another. This 
is the reason why none of the inhibitors that bind to the human enzyme inhibit the E. coli 
enzyme (Liu S. et al)viii. 
 
 
 
Figure 3. Ribbon diagram of a triazolopyrimidine 
inhibitor(DSM1) bound to PfDHODH. Helices are 
displayed in teal, strands are displayed in sand, ligands 
are displayed as space filling balls with FMN in yellow, 
the inhibitor is in pink, orotate is in turquoise, and the 
bound detergent molecule is in gray. The position of the 
detergent corresponds to the position of the shortened 
surface loop truncated in the PfDHODH_384–413 
construct. B, A stereo rapresentation of the DSM1-
binding site. Residues within 4 Å of the bound inhibitor 
are displayed. DSM1 is displayed in pink, and residues 
are displayed in teal. Nitrogen is displayed in blue, 
oxygen is in red, and sulfur is in yellow. Source: Deng et 
al.
xiv 
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Species-selectivity 
It has been found that good human DHODH inhibitors are not usually good pfDHODH 
inhibitors and vice versaxv and the reason can be found in the residues of the ubiquinone 
binding pocket. Deng et al.xiv found that inhibitors bind two sites in the pfDHODH. The site 
A is a highly conserved hydrophobic pocket in which some polar aminoacids (Hys185 and 
Arg265) assure the fundamental H-bridges with the inhibitor. Site B is a more hydrophobic 
pocket and it differs from species to species. The major feature of this pocket is its 
flexibility, which is illustrated by the binding mode of pfDHODH with A77 1726 not 
overlapping with specific pfDHODH inhibitors from a triazolopyrimidine series (DSM1; see 
Figure 3, DSM2, DSM74) except for in site A. The hydrophobic site B pocket can change 
its conformation by the rotation of the residue Phe188. In this way, two different pockets 
are defined and this explains why the plasmodium enzyme can host such different inhibitor 
scaffolds.  
 
Figure 4. The picture shows the possible site B conformations of the parasite pfDHODH enzyme with two different 
inhibitors and the corresponding conformation in the humanDHODH binding site B. 
 
The human enzyme has the same two sites for the inhibitor binding, with the site A very 
similar to the parasite one. However, site B occupies a completely different position in the 
plasmodium enzyme. In fact, site B in pfDHODH has two possible conformations that do 
not share the conformation of site B in hDHODH, which may explain why good hDHODH 
inhibitors are not good pfDHODH inhibitors (Figure 4).  
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Discussion 
Probing 3-benzyl-4-aminocoumarins as novel PfDHODH inhibitors 
4-Aminocoumarins has already been proven as interesting pfDHODH inhibitorsxvi. First, 
coumarins were designed to maintain the fundamental interactions between DSM1 
compound and the pfDHODH pocket. These are two H-bonds occurring between the 
nitrogen in the naphtylamine position and histidine185 and between the pyridine nitrogen 
and arginine265 in DSM1xvii,xiv. The 4-aminocoumarin scaffold was in silico positioned in 
the binding site trying to mime the triazolopyrimidine in the pfDHODH-DSM1 complex 
(PDB 3I65). Calculations suggested that the ring oxygen may interact with the arginine 
residue, while the amino group in the 4-position may interact with the histidine. Some 
derivatives from this scaffold have been tested with the purified parasitic enzyme and with 
human enzyme. The most effective compound had an IC50 of 0.26µM ± 0.018 and more 
than 200 times less effective against the human enzyme, supporting the design hypothesis 
for these compounds (Figure 5).  
 
 
Figure 5. Predicted binding mode of (15) with the protein. The inhibitor is rappresented in green while DSM1 in yellow; the 
arginine and the histidine are displayed in grey. Oxygen atoms are in red, nitrogen atoms in blue. 
 
Even if 3-position lipophilic substitution in the coumarin scaffold has been proven 
beneficial for hDHODH 4-hydroxycoumarin inhibitors, it is not clear if the same substitution 
could increase the binding affinity between 4-aminocoumarin-inhibitors and pfDHODH. For 
this reason, a small series of 4-amino-3-benzylcoumarin derivatives (Figure 6) were 
synthetized and tested with the purified pfDHODH. 
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Figure 6. 4-Amino-3-benzylcoumarin derivatives. 
 
The flexibility of the hydrophobic pocket in the binding site allows the expansion in the 4-
position of the coumarin. For this reason we have synthetized six compounds (4-8,10 ) 
starting from the 4-amino derivative and increasing the length of the amino-alkyl/aromatic 
chain. Tested compounds have been prepared according to Scheme 1.  
 
 
 
 
 
Scheme 1. Synthesis of 4-amino-3-benzylcoumarin derivatives. 
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Probing 4-amino-8-azacoumarins as novel pfDHODH inhibitors 
We also wanted to investigate if a change in the aromatic ring of the coumarin scaffold 
could be beneficial for inhibitors. The first idea was to introduce a nitrogen in the 8-position 
of the coumarin, as in that area the arginine residue of the binding site interact with the 
oxygen from the ring. Hence, the presence of another H-bond acceptor atom may increase 
the affinity between the scaffold and the active site. To investigate this hypothesis, 
molecular modeling was performed on 4-(benzylamino)pyrano[2,3-b]pyridin-2-one, 
comparing the position of the investigated 8-azacoumarin with DSM1. 
 
Figure 7. 4-Amino-8-azacoumarin derivatives. 
 
 
Figure 8. Predicted binding mode of compound (16) with the protein. In purple is depicted the inhibitor, in grey the arginine 
and the histidine residues; Oxygen atoms are displayed in red and nitrogen atoms in blue. 
 
As shown from the modeling (Figure 8), the aza-compound fits well in the binding site and 
the new presumed inhibitor occupies the same position of DMS1, ensuring the correct 
position of the amino-nitrogen and the oxygen involved in the H-bond. From the modeling, 
it seems that the arginine residue may stand at the same distance from the pyridine-
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nitrogen and the ring oxygen, so two different binding modes are possible: in case the H-
bond involves the nitrogen instead of the oxygen, a shift of the molecule toward the mouth 
of the pocket may be considered (Figure 9). Previous studies showed that the benzyl-and 
the indol-derivatives of 4-aminocoumarin are micro molar inhibitors (IC50 around 12µM and 
0.6µM, respectively) of pfDHODH (material unpublished). We wanted to investigate if the 
benzyl-, the indol- and the benzimidazol- derivatives of 4-amino-8-azacoumarin are more 
or less potent of the equivalent 4-aminocoumarin derivatives. 
 
 
Figure 9. The picture shows the different interactions which may occur between the indol derivative and the binding site. 
 
The azacoumarin-derivatives were synthetized according to Scheme 2. 
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Scheme 2. Synthesis of 4-amino-8-azacoumarin derivatives.                     
 
Conclusion 
In summary, in silico design was performed in the search of potent pfDHODH inhibitors. 
The designed 3-benzyl-4-aminocoumarins were found to be inactive probably due to the 
steric hindrance of the aromatic moiety in 3-position. 4-Amino-8-azacoumarin derivatives 
will be tested soon. All the derivatives will be also tested with the human enzyme.  
 
Chemistry 
Unless otherwise noted, starting materials and reagents were obtained from commercial 
suppliers. NMR spectra were recorded on a Bruker Ultra Shield TM 400Plus spectrometer. 
Chemical shifts (δ), determined from residual solvent peaks, are reported in ppm relative 
to TMS while Js are in Hz. All the compounds were confirmed by mass spectrometry 
recorded on Waters Micromass Q-Tof (ESI+ ionization [M+H]+). All the reactions were 
performed under nitrogen atmosphere and dry solvents were obtained from MBraun SPS-
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800 solvents dispenser. All final compounds had a purity ≥95% (254nm) recorded on a 
Hewlett Packard series 1100 HPLC, column XTerraTM MS C18 2.5µm, 2.1x50mm and 
when necessary, compounds were purified using a Gilson preparative HPLC, column 
Zorbax SB-C18 9.4mmx25cm.      
 
Experimentals 
3-Benzyl-4-hydroxy-chromen-2-one (1):xviii 
Benzaldehyde (1.78 g, 0.017 mol) and 4-hydroxychromen-2-one (2.7 g, 0.017 mol)  were 
added to triethylamine formate (18ml) prepared as follow: triethylamine (48.6 g, 0.48 mol)  
was added dropwise to formic acid (55.2 g, 1.2 mol) in an ice-bath. The reaction mixture 
were stirred and heated between 140-150 °C for 2 h. The reaction is allowed to cool 
around 50 °C and then it is poured into cold water (30 mL). The water is then acidified to 
pH 2 with 6M HCl. The suspension is stirred for 15’ then the solid is filtered obtaining a 
light brown crude product that was crystallized from ethanol giving the desired product 
(2.745 g, 65% yield); 1H-NMR(DMSO-d6): 11.67(s, 1H); 7.98(d, 1H J=8.4Hz); 7.61(dd, 1H 
J=7.3-8.4Hz); 7.36(m, 2H); 7.25(m, 4H); 7.16(m, 1H); 3.89(s, 1H). 13C-NMR(DMSO-d6): 
163.6; 162.2; 152.7; 140.4; 132.5; 128.8; 128.7; 126.4; 124.5; 123.9; 116.7(2C); 104.6; 
29.1; 
 
3-Benzyl-4-chloro-chromen-2-one (2): 
3-Benzyl-4-hydroxy-chromen-2-one (2.485 g, 9.8 mmol) were heated to 100 °C in POCl3 
(9 mL) for 6hours, then the excess of POCl3 was distilled off and the residues were 
dissolved in Ethyl acetate (40 mL). The organic phase was washed with diluted NaOH 
repeatedly, then washed with brine and dried over sodium sulfate. The solvent was then 
evaporated in vacuo giving a pale pink crude product that was purified by flash 
chromatography with toluene as eluent obtaining the pure product (2.442 g, 92% yield); 
1H-NMR(CDCl3): 7.88(dd, 1H J=8.54-1.54Hz); 7.55(ddd, 1H J=8.22-7.42-1.56Hz); 7.42(m, 
2H); 7.31(m, 4H); 7.22(t, 1H J=7.3Hz); 4.16(s, 2H); 13C-NMR(CDCl3): 160.8; 152.2; 146.3; 
137.9; 132.6; 129.4; 129.0; 127.2; 127.0; 126.1; 125.1; 119.0; 117.0; 34.1; ESI-MS [M+H]+ 
: 271. 
 
General procedure for amine derivatives (3-7):xix 
To DMSO (2.8 mL) was added 3-benzyl-4-hydroxy-chromen-2-one (250 mg, 0.92 mmol). 
Then 3eq of the corresponding amine were added to the suspension and the mixture was 
stirred at the required temperature (see below). The reaction was then cooled to room 
temperature and cold water (10 mL) was added obtaining a precipitate. The precipitate 
was filtered obtaining a crude solid that was purified by flash chromatography. 
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3-Benzyl-4-(methylamino)chromen-2-one (3): 
The reaction was performed according to general procedure above. Reaction temperature 
and time: room temperature, 3h. Yield: 8%. 1H-NMR(CDCl3): 7.69(dd, 1H J=8.14-1.29Hz); 
7.49(ddd, 1H J=8.52-7.28-1.38Hz); 7.34(dd, 1H J=8.31-1.14Hz); 7.29-7.16(m, 6H); 4.10(s, 
2H); 3.13(s, 3H); 13C-NMR(CDCl3): 164.5; 153.7; 153.4; 140.2; 131.5; 129.1; 128.2; 126.7; 
123.6; 123.3; 118.0; 116.2; 100.2; 34.3; 31.1; ESI-MS [M+H]+ : 266. 
 
3-Benzyl-4-(dimethylamino)chromen-2-one (4): 
The reaction was performed according to general procedure above. Reaction temperature 
and time: room temperature, 8h. Yield: 39%. 1H-NMR(CDCl3): 7.68(dd, 1H J=8.07-1.54 
Hz); 7.48(ddd, 1H J=8.68-7.21-1.57 Hz); 7.35(dd, 1H J=8.27-1.23 Hz); 7.29-7.16(m, 6H); 
4.10(s, 2H); 2.95(s, 6H). 13C-NMR(CDCl3): 164.9; 159.2; 153.5; 140.7; 131.1; 128.8; 
128.3; 126.5; 126.1; 123.8; 119.8; 117.5; 115.9; 43.3; 32.4. ESI-MS [M+H]+ : 280. 
 
4-Anilino-3-benzyl-chromen-2-one (5): 
The reaction was performed according to general procedure above. Reaction temperature 
and time: 90°C, 6 days (1 eq. of sodium carbonate was added to the mixture to increase 
the attack from the aniline). Yield: 40%. 1H-NMR(CDCl3): 7.44(ddd, 1H J=1.51-7.15-8.57 
Hz); 7.36(dd, 1H J=1.02-8.34 Hz); 7.32-7.20(m, 8H); 7.02(m, 2H); 6.81(dd, 2H J=0.63-7.55 
Hz); 4.04(s, 2H). 13C NMR (CDCl3): δ 163.9; 153.7; 149.0; 142.6; 138.8; 131.6; 129.9; 
129.4; 128.5; 127.2; 125.9; 123.7; 123.6; 120.4; 117.6; 116.6; 112.6; 31.6. ESI-MS [M+H]+ 
: 328. 
 
3-Benzyl-4-(benzylamino)chromen-2-one (6): 
The reaction was performed according to general procedure above. Reaction temperature 
and time: 35°C, over night. Yield: 39%. 1H-NMR(CDCl3): 7.59(dd, 1H J=8.17-1.19 Hz); 
7.43(ddd, 1H J=7.24-7.04-1,46 Hz); 7.33-7.23(m, 3H); 7.20-7.06(m, 9H); 4.48(s, 2H); 
3.90(s, 2H).13C NMR ( CDCl3) δ 164.3; 153.6; 153.3; 139.8; 138.8; 131.6; 129.5; 129.2; 
128.5; 128.2; 127.7; 126.8; 123.8; 123.6; 118.1; 116.2; 102.8; 51.4; 31.2. ESI-MS [M+H]+ : 
342. 
 
3-Benzyl-4-(2-phenylethylamino)chromen-2-one (7): 
The reaction was performed according to general procedure above. Reaction temperature 
and time: room temperature, over night. Yield: 82%. 1H-NMR(CDCl3): 7.54(dd, 1H J=1.38-
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8.14 Hz); 7.48(ddd, 1H J=1.46-7.25-8.56 Hz); 7.36-7.16(m, 8H); 7.11(dd, 4H J=1.09-7.73 
Hz); 3.92(s, 2H); 3.72(t, 2H J=6.88 Hz); 2.76(t, 2H J=6.86 Hz). 13C NMR (CDCl3): δ 164.3; 
153.6; 153.5; 139.7; 137.9; 131.5; 129.4; 129.2; 128.3; 127.5; 126.8; 123.8; 123.6; 118.0; 
116.4; 102.7; 48.2; 36.8; 31.1. ESI-MS [M+H]+ : 356. 
 
4-Azido-3-benzyl-chromen-2-one (8): 
3-Benzyl-4-chloro-chromen-2-one (300 mg, 1.1 mmol) were dissolved in dry DMF (5 mL), 
then sodium azide (107 mg, 1.6 mmol) was added to the solution. The mixture was stirred 
at room temperature over-night. Cold water (50 mL) was added to the mixture and the 
suspension was stirred for 20’, then the precipitate was filtered and washed with water. A 
yellow solid was obtained (285 mg, Yield: 65%). 1H-NMR(CDCl3): 7.66(dd, 1H J=1.33-8.05 
Hz); 7.40(m, 1H); 7.24-7.03(m, 7H);3.99(s, 2H). 13C NMR (CDCl3): δ 162.5; 152.7; 146.2; 
138.7; 132.6; 129.1; 128.6; 127.1; 124.8; 123.6; 118.2; 117.5; 116.8; 31.0. ESI-MS [M+H]+ 
: 278. 
 
4-Amino-3-benzyl-chromen-2-one (9):xx 
To a stirred solution of stannous chloride (205 mg, 1.08 mmol) in methanol (2.5 mL), 4-
azido-3-benzyl-chromen-2-one (150 mg, 0.54 mmol) was added portion wise. The 
suspension was stirred at room temperature for 30’ then cold water (15 mL) was added to 
the reaction and the mixture was stirred for 15’ in an ice-bath. The precipitate was filtered 
and washed with water, obtaining a crude product that was purified by flash 
chromatography (eluent toluene/ethyl acetate 8:2) obtaining a pure product (69 mg, Yield: 
57%). 1H-NMR(DMSO): 8.06(d, 1H J=7.57 Hz); 7.57(t, 1H J=7.25 Hz); 7.40-7.05(m, 9H); 
3.81(s, 2H). 13C NMR (100 MHz, DMSO): δ 162.9; 152.9; 151.6; 140.8; 132.0; 128.6; 
128.6; 126.2; 123.9; 123.6; 117.0; 115.2; 95.5; 29.4. ESI-MS [M+H]+ : 252. 
____________________________________ 
2-Chloropyridine-3-carbonyl chloride (10):xxi 
To a suspension of 2-chloropyridine-3-carboxylic acid (2 g, 13 mmol) in dry DCM (15 mL), 
was added dry DMF (0.1 mL) and oxalyl chloride (2.1 mL, 26 mmol) drop wise. the 
suspension was stirred at room temperature for 2h then the volatiles were removed under 
reduced pressure obtaining a pale-yellow crude product which was used for the next step 
without purification. The reaction was checked by TLC and ESI-MS, quenching a sample 
from the mixture in methanol. ESI-MS (sample + methanol) [M+H]+ : 172. 
 
2-[(2-chloro-3-pyridyl)-hydroxy-methyl]malonic acid diethyl esther (11):xxii 
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Dry DCM (30 mL) was added to anhydrous magnesium chloride (870 mg, 9.1 mmol), then 
diethyl malonate (2.4 mL, 15.6 mmol) and triethylamine (4.3 mL, 31.2 mmol) were added. 
The mixture was stirred at room temperature for 1h, then a solution of 2-chloropyridine-3-
carbonyl chloride (2.28 g, 13 mmol) in dry DCM (15 mL) was added drop wise and the 
mixture was stirred for 4h. the reaction was then poured in cold water (40 mL) and the 
water phase was extracted with DCM. The organic phases were collected, washed with 
brine and dried over sodium sulfate. The solvent was removed under reduced pressure 
obtaining a crude product which was purified by flash chromatography (eluent 
DCM/methanol 98:2). the pure product obtained is a red oil (2.49 g, Yield: 64%).1H-
NMR(CDCl3): 13.84(s, 1H); 8.45(dd, 1H J=4.86-1.94 Hz); 7.68(dd, 1H J=7.58-1.94 Hz); 
7.30(dd, 1H J=7.58-4.86 Hz); 4.37(q, 2H J=7.13 Hz); 3.95(q, 2H J=7.13 Hz); 1.37(t, 3H 
J=7.14 Hz); 0.90(t, 3H J=7.14 Hz). 13C NMR (CDCl3 , 100 MHz): δ 174.9; 171.7; 164.7; 
151.0; 149.0; 138.4; 131.4; 122.3; 102.9; 62.3; 61.0; 13.7; 13.3. ESI-MS [M+H]+ : 300. 
 
Ethyl 4-hydroxy-2-oxo-pyrano[2,3-b]pyridine-3-carboxylate (12):xxiii 
Diethyl 2-[(2-chloro-3-pyridyl)-hydroxy-methyl]propanedioate (4.17 g, 14 mmol) was 
dissolved in DCE (20 mL), then methansulfonic acid (0.1 mL) was added and the reaction 
was stirred at reflux for 90’. The volatiles were removed under reduced pressure obtaining 
a crude product which was purified by trituration with water obtaining the pure product 
(2.55 g, Yield: 78%). 1H-NMR(CDCl3): 14.75(s, 1H); 8.68(dd, 1H J=4.76-1.98 Hz); 8.39(dd, 
1H J=7.77-1.98 Hz); 7.38(dd, 1H J=7.77-4.76 Hz); 4.51(q, 2H J=7.13 Hz); 1.46(t, 3H 
J=7.13 Hz). 13C NMR (100 MHz, CDCl3): δ 175.3; 172.2; 159.6; 156.8; 155.2; 135.7; 
121.4; 110.3; 94.1; 63.2; 13.8. ESI-MS [M+H]+ : 236. 
 
4-Hydroxypyrano[2,3-b]pyridin-2-one (13):xxiv 
Ethyl 4-hydroxy-2-oxo-pyrano[2,3-b]pyridine-3-carboxylate (2.54 g, 11 mmol) was added to 
polyphosphoric acid (20 g) and the mixture was heated to 127 °C (the reaction develops 
gas). When the mixture turned homogeneous and did not develop further gas, 50ml of 
water were added. The polyphosphoric acid dissolved slowly while a solid started to 
precipitate. The suspension was stirred in an ice-bath then the solid was filtered and 
washed with water and DCM, obtaining the product (1.5 g, Yield: 85%). 1H-NMR(400 MHz, 
DMSO): 12.86(s, 1H); 8.57(dd, 1H J=4.74-1.86 Hz); 8.26(dd, 1H J=7.68-1.86 Hz); 7.45(dd, 
1H J=7.68-4.78 Hz); 5.64(s, 1H). 13C NMR (100 MHz, DMSO): δ 165.9; 162.1; 159.2; 
152.0; 134.1; 121.5; 111.8; 92.0. ESI-MS [M+H]+ : 164. 
 
4-Chloropyrano[2,3-b]pyridin-2-one(14):xxv 
4-Hydroxypyrano[2,3-b]pyridin-2-one (400 mg, 2.4 mmol) was added to phosphorous 
oxychloride (5 mL) and the reaction was stirred at 100 °C for 15h. Part of the excess of the 
POCl3 was removed by distillation and the residue was dispersed in DCM (50 mL). Then, 
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water (50 mL) was added and sodium hydroxide 5M was added until the pH was around 9. 
The water phase was extracted with DCM, the organic phases collected, washed with 
brine and dried over sodium sulfate. The solvent was removed under reduced pressure 
obtaining a crude product which was purified by flash chromatography on a silica plug 
(eluent DCM) obtaining a pure compound (308mg, Yield: 69%). 1H-NMR(400 MHz, 
CDCl3): 8.61(dd, 1H J=4.78-1.80 Hz); 8.26(dd, 1H J=7.79-1.83 Hz); 7.42(dd, 1H J=7.79-
4.80 Hz); 6.69(s, 1H). 13C NMR (100 MHz, CDCl3): δ 158.7; 158.2; 152.6; 148.9; 135.7; 
121.8; 117.1; 114.0. ESI-MS [M+H]+ : 182. 
 
4-(Benzylamino)pyrano[2,3-b]pyridin-2-one (15):xix 
4-Chloropyrano[2,3-b]pyridin-2-one (100 mg, 0.55 mmol) were dissolved in dry DMSO (1.5 
mL). Benzylamine (0.18 mL, 1.6 mmol) was then added and the reaction was stirred for 2h 
at room temperature. Cold water (4 mL) was added to the reaction and the precipitate was 
filtered, obtaining a crude product which was purified by flash chromatography (eluent 
DCM/methanol 96:4). A pure compound was obtained (33 mg, Yield: 24%). 1H-NMR(400 
MHz, DMSO): 8.61(dd, 1H J=7.90-1.70 Hz); 8.57-8.48(m, 2H); 7.47(dd, 1H J=7.86-4.74 
Hz); 7.42-7.32(m, 4H); 7.27(m, 1H); 5.13(s, 1H); 4.53(d, 2H J=5.85 Hz). 13C NMR (100 
MHz, DMSO): δ 161.8; 158.8; 153.3; 151.4; 138.1; 133.3; 129.1; 127.8; 127.6; 120.8; 
110.4; 83.2; 45.7. ESI-MS [M+H]+ : 253. 
 
4-(1H-Indol-2-ylmethylamino)pyrano[2,3-b]pyridin-2-one (16):xix 
4-Chloropyrano[2,3-b]pyridin-2-one (70 mg, 0.39 mmol) was dissolved In dry DMSO (1 
mL), then 1H-indol-2ylmethanamine (113 mg, 0.8 mmol) was added and the reaction was 
stirred for 2.5h at room temperature. Cold water (4 mL) was added to the reaction and the 
precipitate was filtered obtaining a crude product which was purified by trituration in DCM 
obtaining a pure compound (25 mg, Yield: 22%). 1H-NMR(400 MHz, DMSO): 11.08(s, 1H); 
8.61(dd, 1H J=7.96-1.75 Hz); 8.54(dd, 1H J=4.74-1.73 Hz); 8.40(t, 1H J=5.49 Hz); 7.52-
7.43(m, 2H); 7.34(dd, 1H J=0.81-8.04 Hz); 7.04(ddd, 1H J=8.16-7.09-1.21 Hz); 6.96(ddd, 
1H J=7.98-7.14-1.04 Hz); 6.39(d, 1H J=1.07 Hz); 5.30(s, 1H); 4.66(d, 2H J=5.39 Hz). 13C 
NMR (100 MHz, DMSO): δ 161.9; 158.8; 153.4; 151.4; 136.8; 135.6; 133.5; 128.5; 121.4; 
120.8; 120.2; 119.5; 111.6; 110.4; 100.1; 83.2; 40.2. ESI-MS [M+H]+ : 292. 
 
4-(1H-Benzimidazol-2-ylmethylamino)pyrano[2,3-b]pyridin-2-one(17):xix 
4-Chloropyrano[2,3-b]pyridin-2-one (70 mg, 0.39 mmol) was dissolved in dry DMSO (1 
mL), then 1H-benzimidazol-2-ylmethanamine (172 mg, 0.8 mmol) was added and the 
reaction was stirred at room temperature over-night. Cold water (4 mL) were then added to 
the reaction and the precipitate was filtered obtaining a crude product which was triturated 
twice in DCM obtaining a more pure product (14 mg, Yield: 12%).1H-NMR(400 MHz, 
DMSO): 12.44(s, 1H); 8.67-8.51(m, 3H); 7.65-7.44(m, 3H); 7.16(m, 2H); 5.24(s, 1H); 
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4.76(d, 2H J=5.64 Hz). 13C NMR(100 MHz, DMSO): δ161.9; 158.8; 153.8; 151.6; 151.5; 
133.6; 122.3; 120.9; 110.5; 83.5; 41.0. ESI-MS [M+H]+ : 293. 
 
pfDHODH inhibition assays 
For determination of inhibition and IC50 values of Plasmodium falciparum DHODH the 
recombinant enzyme was used in an in vitro enzyme assay with N-terminally truncated 
recombinant DHODHxxvi. The assay is based on coupling of the ubiquinone reduction to 
the redox dye 2,6-dichloroindophenol (DCIP)xxvii. The reduction of DCIP was monitored 
photometrically by decreasing absorption at 600nm. The test solutions contained 60µM 
DCIP, 150 mM KCl, 50mM TRIS/HCl pH 7.8, 0.1% Triton X-100, 20µM decylubiquinone 
and 200µM DHO. Synthesized compounds were dissolved in DMSO and normally added 
to a final concentration of 1% DMSO. A higher concentration of DMSO, 5%, was used to 
prevent precipitation and measure inhibition of compounds with IC50 ‘s higher than 100µM. 
No inhibition of enzyme function was found in the control containing 5% DMSO. 
 
Molecular modeling 
The Schrodinger 2013 software suite was used for molecular modeling. Energy 
minimization was performed with Macromodel, utilizing the OPLS-2005 force field and the 
GB/SA model for water solvation. The Protein Preparation Wizard was utilized on the 
crystal structure, to add hydrogens, assign charges, and optimize hydrogen bond 
networks. The crystal waters with hydrogen bond interactions to the FMN prosthetic group 
were included in the model. Pictures were obtained from PyMOL. 
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